Home > Oncology > ASCO 2022 > Gynaecological Cancers > Primary results of rucaparib in ovarian cancer 

Primary results of rucaparib in ovarian cancer 

Presented By
Prof. Bradley Monk, University of Arizona, AZ, USA
Conference
ASCO 2022
Trial
Phase 3, ATHENA-MONO
Doi
https://doi.org/10.55788/ef71bd62
First-line rucaparib maintenance therapy after platinum-based chemotherapy improved the progression-free survival (PFS) of patients with stage III–IV ovarian cancer in the ATHENA-MONO trial. Further tumour reductions were reported following treatment with rucaparib.   The efficacy of the PARP inhibitor rucaparib has been established in patients with platinum-sensitive recurrent ovarian cancer [1]. Also, PARP inhibitors have delivered PFS benefits as first-line maintenance treatment [2]. However, ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on